

Localized lymphadenopathy due to leishmanial infection

G. Harms, Johannes Zenk, S. Martin, Maria Kokozidou, W. Püschel, U. Bienzle, H. M. Seitz

Angaben zur Veröffentlichung / Publication details:

Harms, G., Johannes Zenk, S. Martin, Maria Kokozidou, W. Püschel, U. Bienzle, and H. M. Seitz. 2001. "Localized lymphadenopathy due to leishmanial infection." *Infection* 29 (6): 355–56. <https://doi.org/10.1007/s15010-001-1080-3>.

Nutzungsbedingungen / Terms of use:

licgercopyright

Dieses Dokument wird unter folgenden Bedingungen zur Verfügung gestellt: / This document is made available under the following conditions:

Deutsches Urheberrecht

Weitere Informationen finden Sie unter: / For more information see:

<https://www.uni-augsburg.de/de/organisation/bibliothek/publizieren-zitieren-archivieren/publizieren>



Localized Lymphadenopathy Due to Leishmanial Infection

G. Harms, J. Zenk, S. Martin, M. Kokozidou, W. Püschel, U. Bienzle, H. M. Seitz

Abstract

A 25-year-old female patient presented with an isolated cervical lymph node enlargement several months after having returned from Spain and Latin America. She had no other signs or symptoms of disease. *Leishmania infantum/chagasi* was identified as the causative agent. With extended travel activities localized lymph node enlargement due to leishmanial infection should be included in the differential diagnosis of lymphadenopathy of unknown origin.

Key Words

Leishmaniasis · Localized lymphadenopathy · *Leishmania infantum/chagasi*

Introduction

The leishmaniasis have been considered classical tropical infections. However, due to the increasing international travel activities and the inclusion of visceral leishmaniasis as a complication of AIDS, they have become a topic of general medical concern in the developed world.

Commonly, visceral leishmaniasis is a chronic infectious disease of the monocyte-macrophage system characterized by fever, pancytopenia, hepatosplenomegaly and weight loss. Cutaneous leishmaniasis presents as single or multiple papular, nodular or ulcerous skin lesions. We describe a case of an isolated cervical lymph node enlargement due to leishmanial infection without any cutaneous or systemic manifestations.

Case Report

A 25-year-old German student presented to the otorhinolaryngology outpatient department with an indolent left supraclavicular lymph node enlargement of 1-month duration. She did not complain about any symptoms. She had been on a 2-week hiking tour in the Pyrenees of northern Spain 4 months before, to Guatemala and Mexico 16 months before and to Ecuador and Peru 40 months before the onset of the lymph node swelling. She

recalled occasional insect bites during these travels but no skin lesions.

Apart from the isolated lymphadenopathy, the physical examination and an abdominal ultrasonography were unremarkable. No skin abnormalities indicative of current or healed cutaneous lesions were detected. Laboratory tests including hematological (RBC, WBC, differential and platelet count, erythrocyte sedimentation rate) and biochemical parameters (aspartate and alanine aminotransferase, IgG, IgM) were all normal. Since symptomatic and antibiotic treatment showed no improvement, the lymph node was excised. Histological examination revealed *Leishmania* amastigotes within macrophages. Antibodies to *Leishmania donovani* were detected in low concentration (1 : 160) by immunofluorescence (IFT). A culture from biopsy material grew *Leishmania* which were identified as *Leishmania infantum/chagasi* by DNA-fingerprinting. The search for *Leishmania* in peripheral blood by PCR was negative. Due to the lack of any signs or symptoms indicative of systemic disease, further invasive investigations such as a bone marrow aspirate were not done. The patient was not infected by HIV or otherwise immunocompromised.

The patient was treated with liposomal amphotericin B (AmBisome®, 3mg/kg/d on days 1–5 and on day 10). Titers of antibodies to *L. donovani* had decreased to marginal concentrations (IFT 1 : 20) 2 and 6 months after treatment. Ultrasonography of the neck performed 2 and 6 months after treatment did not reveal any further lymph node enlargement.

Discussion

Due to the preference of *Leishmania* parasites for the monocyte-macrophage system, generalized lymphadenopathy can occur with classical visceral leishmaniasis [1]. Lymph node enlargement associated with cutaneous le-

G. Harms (corresponding author), **U. Bienzle**

Institute of Tropical Medicine and Medical Faculty Charité, Humboldt University Berlin, Spandauer Damm 130, D-14050 Berlin, Germany; e-mail: gundel.harms@charite.de

J. Zenk

Dept. of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Homburg/Saar, Germany

S. Martin, M. Kokozidou, H.M. Seitz

Institute of Medical Parasitology, Bonn University, Bonn, Germany

W. Püschel

Dept. of Pathology, Saarland University, Homburg/Saar, Germany

sions caused by *Leishmania tropica* or by *Leishmania major* has been reported [2]. In the New World, lymphadenopathy may accompany or even precede skin lesion due to the *Leishmania braziliensis* complex, indicating that spread from the skin to lymph nodes occurs early in the course of infection [3–5]. However, localized lymphadenopathy without cutaneous or systemic manifestations is unusual and has been rarely reported [4–15]. Most cases were diagnosed by surgical biopsy because of a suspected lymphoma. Interestingly, in most of these patients the lymph node enlargement affected the left neck without further specification. In our case, the affected lymph node was located on the left neck at the junction of the ductus thoracicus which drains the lymph system of the viscera. It may be speculated that this particular location hints at a visceral involvement.

Although certain *Leishmania* spp. are more commonly associated with certain clinical syndromes than with others, there is a spectrum of clinical manifestations that can be seen with infections caused by the same species. This is particularly true for *L. infantum* which may cause the whole spectrum of disease, namely visceral, cutaneous and mucosal manifestations. The mechanisms underlying tissue tropism are poorly understood. However, the extent of the organ involvement in infections with *Leishmania* spp. mainly depends on the ability of the host to generate an effective cellular response [16]. Accordingly, dissemination of the parasites increases with decreasing immunocompetence. In fact, in patients with advanced HIV disease, parasites will eventually invade all organs including the skin and can appear in considerable numbers in the peripheral blood.

The absence of organ and laboratory abnormalities and the confinement to one lymph node indicate that our patient was able to control the infection over a period of several months. However, a change in immunocompetence, such as that occurring during pregnancy, might initiate generalization of the infection.

We assume that the infection was most likely contracted in northern Spain; all cases reported in this region so far were caused by *L. infantum* and the patient's visit to Spain was the most recent one. Due to the genetic similarities between *L. infantum* and *L. chagasi*, a differentiation of the two species is hardly possible.

The patient was treated with liposomal amphotericin B (AmBisome®), a drug which concentrates in macrophages, the target cells of *Leishmania*. It is currently the most effective and least toxic drug and, due to its short application schedule, the most practical treatment for leishmaniasis [17–19].

We conclude, that localized lymph node enlargement due to infection with *Leishmania* needs to be included in the spectrum of unusual presentations of leishmanial infections and should be considered in the differential diagnosis of lymphadenopathy of unknown origin.

References

1. World Health Organization: Manual on visceral leishmaniasis control. WHO, Division of Control of Tropical Diseases, Geneva 1996.
2. Gafaar A, Ismail A, El Kadaro A, Hashim E, Khalil EAG, El Hassan AM: Necrotizing and suppurative lymphadenitis in *Leishmania major* infections. *Trop Med Int Health* 1996; 1: 243–250.
3. Barral A, Barral-Neto M, Almeida R, de Jesus AR, Grimaldi Jr G, Netto EM, Santos I, Bacellar O, Carvalho EM: Lymphadenopathy associated with *Leishmania braziliensis* cutaneous infection. *Am J Trop Med Hyg* 1992; 47: 587–592.
4. Barral A, Guerreiro J, Bomfim G, Correia D, Barral-Netto M, Carvalho EM: Lymphadenopathy as the first sign of human cutaneous infection by *L. braziliensis*. *Am J Trop Med Hyg* 1995; 53: 256–259.
5. Sousa A de Q, Parise ME, Pompeu MML, Filho JMC, Vasconcelos IAB, Lima JWO, Oliveira EG, Vasconcelos AW, David JR, Maguire J: Bubonic leishmaniasis: a common manifestation of *Leishmania (Viannia) braziliensis* infection in Ceara, Brazil. *Am J Trop Med Hyg* 1995; 53: 380–385.
6. Chung HL: Localized leishmaniasis of the lymph gland. *Chin Med J (Engl)* 1942; 62: 284–292.
7. Angevine DH, Hamilton TR, Wallace FG, Hazard JB: Lymph nodes in leishmaniasis: report of two cases. *Am J Med Sciences* 1945; 2190: 33–38.
8. Bell DW, Carmichael JAG, Williams RS, Holman RL, Stewart PD: Localized leishmaniasis of lymph nodes. *BMJ* 1958; 1: 740–743.
9. Daneshbod K: Localized adenitis due to *Leishmania* simulating toxoplasmosis. *Am J Clin Path* 1978; 69: 46–47.
10. Azadeh B: Localized *Leishmania* lymphadenitis: a light and electron microscope study. *Am J Trop Med Hyg* 1985; 43: 447–455.
11. Kumar PV, Hambarsoomina B, Vaezzadeh K: Fine needle cytology of localized *Leishmania* lymphadenitis. *Acta Cytol* 1986; 31: 14–16.
12. Morsy TA, Mangoud AM, Aly MA, Farrag AM: Lymphatic leishmaniasis: An adult case without visceral involvement from Sharkia Governorate. *J Egypt Soc Parasitol* 1992; 22: 533–537.
13. Tallada N, Raventos A, Martinez S, Compano C, Almirante B: *Leishmania* lymphadenitis diagnosed by fine-needle aspiration biopsy. *Diag Cytopathol* 1993; 9: 673–676.
14. Peachey AM, Irvine GH, White H: Visceral leishmaniasis: an unusual cervical presentation. *Br J Oral Maxillofac Surg* 1994; 32: 325–327.
15. Vera-Alvarez J, Marigil-Gomez M, Abascal-Aborreta M, Lacasa-Laliena M: Diagnosis of localized *Leishmania* lymphadenitis by fine needle aspiration cytology. *Acta Cytol* 1999; 43: 529–553.
16. Zwingenberger K, Harms G, Pedrosa C, Omena S, Neifer S: Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon- γ production. *Clin Immunol Immunopathol* 1990; 57: 242–249.
17. Gradoni L, Bryceson ADM, Desjeux P: Treatment of Mediterranean visceral leishmaniasis. *Bull WHO* 1995; 73: 191–197.
18. Sundar S, Murray HW: Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. *J Infect Dis* 1996; 173: 762–765.
19. Meyerhoff A: US food and drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. *Clin Infect Dis* 1999; 28: 42–48.